Target price: RM4.4
Catalyst:
- Multiple expansion of production lines.
- Results for quarter ended 31 March 2016 is expected to growth 15% to RM45million based on update from management.
- Dual listing of shares in SGX.
- Bumper dividend of 40 - 45 cents per share on sale of plot of land in Serendah.
- Weak GBP to lower cost for NHS investment.
ronnietan
Can you post the whole US report?
2016-04-11 11:39